| 20.99 0 (0%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Covetrus, Inc. functions as a technology and services provider for the animal health sector. The company supplies a comprehensive range of animal health consumables, including its own branded and proprietary items, along with diverse equipment (small and large), laboratory supplies, and associated repair services. It further offers a full spectrum of pharmaceuticals—encompassing branded, generic, and vaccine products, surgical instruments, diagnostic kits, infection control solutions, parasiticides, and nutritional supplements—to both wholesale and retail clients. Beyond physical goods, Covetrus delivers critical value-added services such as inventory management, e-commerce platforms, and professional development programs for veterinary practitioners. Its technology portfolio includes practice management software, data analytics applications, and client communication tools aimed at boosting operational efficiency and enhancing business health. These integrated offerings extend to client reminders, data backup, hardware sales and support, and credit card processing capabilities for veterinary practices and clinics. Additionally, the company manages the distribution of finished pharmaceutical products and offers specialty compounding services, complemented by logistics, manufacturer incentives, and data integration support. Covetrus supports veterinary practices and animal health clinics across the companion animal, equine, and livestock sectors, primarily within North America, Europe, and the Asia Pacific. Established in 2018 under the name HS Spinco, Inc. and headquartered in Portland, Maine, Covetrus, Inc. transitioned to private ownership on October 13, 2022.
Fri, 27 Feb 2026
Covetrus $70 Million Securities Class Action Settlement - Claim Depot
Mon, 13 Jun 2022
Deal Diary: Debevoise, Ropes Aid CD&R, TPG in Covetrus Buyout - thedeal.com
Wed, 25 May 2022
CD&R, TPG Take Covetrus Private In $4B Deal - Yahoo Finance
Wed, 25 May 2022
Covetrus to Be Taken Private for $4 Billion - Barron's
Wed, 25 May 2022
Maine’s largest public company, Covetrus, agrees to be privately acquired for $4B - Mainebiz
Wed, 09 Dec 2020
Covetrus Completes Separation from Former Parent Company - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|